Shortwave Life Sciences (AQSE:PSY) Receivables Turnover : 0.00 (As of . 20)

View and export this data going back to 2022. Start your Free Trial

What is Shortwave Life Sciences Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Shortwave Life Sciences's Revenue for the six months ended in . 20 was £0.00 Mil. Shortwave Life Sciences's average Accounts Receivable for the six months ended in . 20 was £0.00 Mil.

Shortwave Life Sciences Receivables Turnover Historical Data

The historical data trend for Shortwave Life Sciences's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shortwave Life Sciences Receivables Turnover Chart

Shortwave Life Sciences Annual Data

Trend

Receivables Turnover

Shortwave Life Sciences Semi-Annual Data

Receivables Turnover

Competitive Comparison of Shortwave Life Sciences's Receivables Turnover

For the Biotechnology subindustry, Shortwave Life Sciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shortwave Life Sciences's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shortwave Life Sciences's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Shortwave Life Sciences's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

Shortwave Life Sciences Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Shortwave Life Sciences's Receivables Turnover for the fiscal year that ended in . 20 is calculated as

	Receivables Turnover (A: . 20 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: . 20 )	/ (	(Accounts Receivable (A: . 20 )	+	Accounts Receivable (A: . 20 ))	/	count )
=		/ (	(	+	)	/	1 )
=		/	0
=	N/A

Shortwave Life Sciences's Receivables Turnover for the quarter that ended in . 20 is calculated as

	Receivables Turnover (Q: . 20 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: . 20 )	/ (	(Accounts Receivable (Q: . 20 )	+	Accounts Receivable (Q: . 20 ))	/	count )
=		/ (	(	+	)	/	1 )
=		/	0
=	N/A

Shortwave Life Sciences (AQSE:PSY) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Shortwave Life Sciences Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Shortwave Life Sciences's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Shortwave Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shortwave Life Sciences PLC (AQSE:PSY) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.shortwavelifesciences.com

Shortwave Life Sciences PLC is a biopharmaceutical company focused in advancing pioneering therapies in mental health care, also it is involved in developing novel drug combinations and delivery methods to treat patients suffering from mental health disorders. It identifies, operates and creates value from early-stage, breakthrough initiatives, with an initial focus on eating disorders.